Buy APLS near 28.9 target 36.47 stop loss @ 28.82 Details The technical summary data tells us to buy APLS near 28.9 with an ...

WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at HC Wainwright reduced their FY2024 earnings ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Wedbush decreased their FY2024 earnings per share (EPS) estimates ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024.

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

RBC Capital Mkts has recently initiated Apellis Pharmaceuticals Inc (APLS) stock to Sector Perform rating, as announced on October 25, 2024, according to Finviz. Earlier, on October 16, 2024, William ...

Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.

Check the time stamp on this data. Updated AI-Generated Signals for Apellis Pharmaceuticals Inc. (APLS) available here: APLS.

Apellis Pharmaceuticals Inc (NASDAQ:APLS) is set to release its Q3 2024 earnings on Nov 5, 2024. The consensus estimate for ...